Reviva Pharmaceuticals files $150M mixed securities shelf 16:1601/2601/26/22
Reviva Pharmaceuticals initiated with a Buy at H.C. Wainwright » 06:0701/2401/24/22
H.C. Wainwright analyst…
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Reviva Pharmaceuticals with a Buy rating and $10 price target. Reviva is an emerging specialty biopharmaceutical company focusing on the development of a next-generation antipsychotic agent, brilaroxazine, Selvaraju tells investors in a research note. The analyst says brilaroxazine "possesses a highly advantageous pharmacological profile."
|Over a week ago|
Reviva Pharmaceuticals: FDA clears Phase 3 trial of brilaroxazine » 06:1001/1001/10/22
Reviva Pharmaceuticals announced the U.S. FDA has notified the company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia. "We believe that FDA clearance to proceed with initiation of a pivotal Phase 3 trial, as well as an additional Phase 3 trial focused on long-term safety, represents a transformative milestone that may support the filing and approval of a new drug application for our lead candidate brilaroxazine in patients with schizophrenia. Both Phase 3 trials will be initiated simultaneously, with the long-term safety study designed to supplement efficacy and safety data from the pivotal trial," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "Collectively these two trials may provide a robust Phase 3 assessment of brilaroxazine in patients with schizophrenia that we believe will complement our successful Phase 2 study. We remain highly encouraged by the therapeutic potential of brilaroxazine and look forward to initiating both Phase 3 trials by the end of January 2022."
|Over a month ago|
Reviva Pharmaceuticals reports Q3 EPS (12c), consensus (23c) » 08:2011/1511/15/21
As of September 30, the…
As of September 30, the company's cash totaled approximately $33.5M compared to approximately $0.35M a year ago."We look forward to initiating two Phase 3 trials evaluating both the efficacy and safety, as well as long-term safety of brilaroxazine in adults with schizophrenia by year-end," said CEO of Reviva. "We are highly encouraged by the therapeutic potential brilaroxazine demonstrated in our successful Phase 2 trial for the treatment of schizophrenia and expect to begin regulatory submissions to the FDA for pulmonary indications including IPF and PAH by the end of 3Q22."
|Over a quarter ago|
Reviva Pharmaceuticals announces 2021 anticipated events, targeted milestones » 08:5208/1608/16/21
Anticipated Events and…
Anticipated Events and Targeted Milestones for 2021: Initiate a pivotal, double-blind Phase 3 study in acute schizophrenia; Regulatory submissions to the U.S. Food and Drug Administration for initiating Phase 2 studies in pulmonary arterial hypertension and idiopathic pulmonary fibrosis; Pursue partnership opportunities for the development of our pipeline; Evaluate grant and other non-dilutive financing opportunities for our product candidates from relevant Federal and State Agencies and Foundations
Reviva Pharmaceuticals expects cash to cover expenses into 2H22 » 08:5208/1608/16/21
As of June 30, 2021, the…
As of June 30, 2021, the Company's cash and cash equivalents totaled approximately $35.8 million compared to approximately $0.2 million for the same period in 2020. Reviva believes that based on the current operating plan and financial resources, the Company's cash and cash equivalents at the quarter end June 30, 2021 will be sufficient to cover general operating expenses into the second half of 2022.
Reviva Pharmaceuticals reports Q2 EPS (23c) vs. (58c) last year » 08:5108/1608/16/21
"We believe the…
"We believe the recent closing of our successful public offering, resulting in gross proceeds of $34.5 million, supported by institutional investors, provides the capital resources to proceed with a pivotal Phase 3 trial of brilaroxazine in patients with schizophrenia," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "Brilaroxazine demonstrated clinical benefit across the hallmark symptoms of schizophrenia and we expect to initiate our upcoming Phase 3 trial in Q4-2021."
Reviva Pharmaceuticals initiated with a Buy at Maxim » 08:0307/2607/26/21
Maxim analyst Jason…
Maxim analyst Jason McCarthy initiated coverage of Reviva Pharmaceuticals with a Buy rating and $10 price target. The company is developing its lead asset, RP5063, for the treatment of schizophrenia and respiratory indications including idiopathic pulmonary fibrosis and pulmonary arterial hypertension, the analyst tells investors in a research note. Reviva's RP5063 features a multimodal mechanism of action, which is "more completely" addressing the mix of positive, negative, and cognitive symptoms associated with schizophrenia, McCarthy adds.
Reviva Pharmaceuticals initiated with a Buy at Maxim » 07:4707/2607/26/21
Maxim analyst Jason…
Maxim analyst Jason McCarthy initiated coverage of Reviva Pharmaceuticals with a Buy rating and $10 price target.
Reviva Pharmaceuticals added to Russell Microcap Index » 07:1406/2806/28/21
Reviva Pharmaceuticals Holdings announced it has joined the broad-market Russell Microcap Index at the conclusion of the Russell U.S. Indexes annual reconstitution. The updated Index will become effective after the U.S. equity market opens today, Monday June 28, 2021.